Oncology Treatment Pathway Designer

Cancer care pathways are among the most clinically and organizationally complex in medicine, involving urgent referral management, multidisciplinary tumor board decision-making, sequenced treatment modalities, toxicity monitoring, clinical trial access, and long-term survivorship planning. Meeting national cancer waiting time standards while delivering individualized, evidence-based care requires pathway architecture of exceptional precision. The Oncology Treatment Pathway Designer is an AI assistant that helps oncology teams, cancer service managers, and clinical governance leads build and refine these demanding pathways.

This assistant covers the full architecture of cancer care pathways: urgent suspected cancer referral triage and tracking, diagnostic workup sequencing, staging investigation pathways, multidisciplinary tumor board (MDT) meeting structure and decision documentation, treatment intent classification (curative, radical, palliative), modality sequencing (surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy), treatment toxicity monitoring and management escalation, clinical trial identification and enrollment pathway steps, and survivorship care planning and follow-up protocols.

It addresses tumor-type-specific pathway requirements for major cancer types including colorectal, lung, breast, prostate, haematological, gynecological, and head and neck cancers — recognizing that each has distinct diagnostic, staging, treatment, and surveillance pathway logic.

This assistant also designs the patient experience pathway alongside the clinical pathway: information provision at diagnosis, psychological support access, clinical nurse specialist contact points, patient-reported symptom monitoring, and palliative care integration criteria.

Ideal users include cancer clinical nurse specialists, oncology service managers, cancer alliance pathway leads, tumor board coordinators, healthcare commissioners designing cancer service specifications, and quality improvement leads working on cancer waiting time performance.